clinical trial · NCT06975722
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
Ulcerative ColitisSAR442970Placebo
brief summary
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
started
Jul 7, 2025
primary completion
Dec 17, 2026
completion
Oct 17, 2029
last updated
Oct 2, 2026
official title
A Phase 2b, Multi-national, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Followed by a Long-term Extension to Evaluate the Efficacy and Safety of Brivekimig in Adult Participants With Moderate to Severe Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol